Advertisement

Clinical Epigenetics

, 10:106 | Cite as

Correction to: Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer

  • Rubén Rodríguez Bautista
  • Alette Ortega Gómez
  • Alfredo Hidalgo Miranda
  • Alejandro Zentella Dehesa
  • Cynthia Villarreal-Garza
  • Federico Ávila-Moreno
  • Oscar Arrieta
Open Access
Correction
  • 234 Downloads

Correction

Upon publication of the original article [1], the authors noticed that the Figs. 1, 2 and 3 were incorrectly given. The correct Figs. 1, 2 and 3 are given below.
Fig. 1

Proposed five functional archetypes for the lncRNA mechanisms. 1. Decoys: lncRNAs can titrate away transcription factors and other proteins away from chromatin, or titrate the protein factors into nuclear subdomains. 2. Signals: lncRNAs expression can faithfully reflect the combinatorial actions of transcription factors (colored ovals) or signaling pathways to indicate gene regulation by space and time. 3. Guides: lncRNAs may recruit chromatin-modifying enzymes to gene-promoter targets, either in Cis (near the genetic region of the lncRNA transcription) or in Trans into distant target genes. 4. Scaffolds: lncRNAs may bring together multiple proteins to conform ribonucleoprotein complexes. The lncRNA-RNP may act on chromatin as illustrated to affect histone code modifications. In other instances, the lncRNA scaffold is structural and stabilizes nuclear structures or signaling complexes 5. Sponge: lncRNAs that by complementarity of bases succeed in matching or sequestering sequences of small non-coding RNAs, such as miRNAs, are controlling bioavailability of miRNAs, vs. lncRNAs themselves, with the functional biological repercussions at cellular or physiological level. RNA-induced silencing complex RISC

Fig. 2

A molecular mechanism model for lncRNAs involved in the tumorigenesis of human TNBC. a lincRNA-RoR as a miR-145 inhibitor (oncogene miRNA). b MALAT1 as a competitive endogenous RNA of miR-1 (tumor suppressor miRNA). c LINK-A as a component of ribonucleoprotein complexes, example shows the regulations of HIF1α pathway. ARF6 ADP-ribosylation factor 6, UTR 3′ untranslated region 3, RISC RNA-induced silencing complex, HB-EGF heparin-binding EGF-like growth factor, EGFR epidermal growth factor receptor, GPNMB transmembrane glycoprotein NMB, BLK B lymphocyte kinase, LRRK2 leucine-rich repeat kinase 2, HIF1α hypoxia-inducible factor 1-alpha, vascular endothelial growth factor VEGF, iNOS inducible nitric oxide synthase, IGF-2 insulin-like growth factor 2, RNP ribonucleoprotein

Fig. 3

Epigenetic implications of lncRNAs in the development of TNBC. a MALAT1 regulated by KDM5B and has-miR-448. b LOC554202 as a host gene of miR-31 (tumor suppressor miRNA), WAVE3 (WAS protein family member 3) KDM5B (lysine-specific demethylase 5B also known as histone demethylase JARID1B), H3K4me3 (trimethylation of lysine 4 on the histone H3 protein subunit), H3K4me1 (monomethylation of lysine 4 on the histone H3 protein subunit), hsa-miR-448 (also known miRNA448), BRCA1/2 (breast cancer 1/2), pRB (retinoblastoma protein), CAV 1 (caveolin 1) HOXA5 (Homeobox protein Hox-A5), SFN (Stratifin), CH3 (methyl group), and RhoA (Ras homolog gene family, member A)

The original article has been corrected.

Reference

  1. 1.
    Bautista RR, Gómez AO, Miranda AH, Dehesa AZ, Villarreal-Garza C, Ávila-Moreno F, Arrieta O. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non-and triple-negative breast cancer. Clin Epigenetics. 2018;10(1):88.CrossRefGoogle Scholar

Copyright information

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Rubén Rodríguez Bautista
    • 1
    • 2
  • Alette Ortega Gómez
    • 1
  • Alfredo Hidalgo Miranda
    • 3
  • Alejandro Zentella Dehesa
    • 4
  • Cynthia Villarreal-Garza
    • 5
  • Federico Ávila-Moreno
    • 6
    • 7
  • Oscar Arrieta
    • 1
  1. 1.Thoracic Oncology Unit and Laboratory of Personalized MedicineInstituto Nacional de Cancerología (INCan)Mexico CityMexico
  2. 2.Biomedical Science Doctorate ProgramNational Autonomous University of MexicoMexico CityMexico
  3. 3.Cancer Genomics LaboratoryINMEGENMexico CityMexico
  4. 4.Biochemistry Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránMexico D.FMexico
  5. 5.Breast Oncology DepartmentNational Cancer Institute of MexicoMexico CityMexico
  6. 6.Lung Diseases And Cancer Epigenomics Laboratory, Biomedicine Research Unit (UBIMED), Facultad de Estudios Superiores (FES) IztacalaNational University Autonomous of México (UNAM)Mexico CityMexico
  7. 7.Research Unit, National Institute of Respiratory Diseases (INER) “Ismael Cosío Villegas”Mexico CityMexico

Personalised recommendations